momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lynn who wrote (11571)	5/31/2018 9:51:06 PM
From: Miljenko Zuanic	Read Replies (1) of 12215

He Lenn, On this tread we were following MDGL/VKTX and other NASH players from 2-2017 (or early). Yes, data (released and some additional at CC) for 3196 are good, but that does not stop anyone to be critical and gain as much insight as possible, to properly value candidate. From the call it seams that subjects baseline data indicate that they were bit light on fibrosis and mild on NASH score, so drug effect (2 points NASH reduction) should be reduced by placebo effects (small trials, small subjects #, hard to see was there any imbalance or "sensitivity"....biopsy pathologist and biopsy in general may have high level/range of spread). Some other bio-market results favor and support strong candidate results. We all appreciate stock price move like today for MDGL (fucxx short when they are trying to take control)...hope you are enjoining your gains and hope there may be many to comes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next